Hbitos nutricionales y relacin con la comida
The New Phase 3 Numbers Here is the new July 23 data in plain language: TRIUMPH-2: 20.8% average weight loss at 80 weeks with 12 mg, plus A1C reductions up to 1.6 percentage points TRIUMPH-3: 22.6% average weight loss at 80 weeks with 12 mg The most common adverse events were gastrointestinal and generally mild to moderate Lilly plans to submit its BLA to the FDA in Q1 2027 The TRIUMPH-2 population had obesity or overweight plus type 2 diabetes, which makes the weight-loss result especially relevant because it came in a harder-to-treat metabolic group
Interestingly, he said, weight-loss surgery did not appear to have the same effect as weight-loss medications
CagriSema combination therapy: Synergistic effects of cagrilintide and semaglutide
Wang J, Ke T, Zhang X, Chen Y, Liu M, Chen J, Luo W
Section 503A pharmacies compound medications based on individual prescriptions